Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui) is a leading global pharmaceutical company headquartered in China focused on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Hengrui has focused its R&D efforts on oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Hengrui ranked 8th on the list of "Top 25 Global Pharma Companies by Pipeline Size" published by Citeline in 2024. Hengrui has spent more than US$5 billion (over RMB40 billion) on R&D in recent years and has built a large-scale, professional, and comprehensive innovative R&D team of more than 5,500 people with 14 R&D centers around the world, along with several subsidiaries in the U.S., Europe, Australia, and Japan. Hengrui currently has 18 commercialized new molecular entity drugs and 4 other innovative drugs. As of December 31, 2024, Hengrui was conducting approximately 400 clinical trials for more than 90 innovative drug candidates and filed 2,609 patent applications in the Greater China region. Hengrui has established manufacturing facilities across China and its products have been commercialized in more than 40 countries. By the end of 2024, Hengrui had initiated over 20 overseas clinical trials. Hengrui actively facilitates the transformation of its R&D findings through international collaborations, resulting in 12 out-licensing transactions for its innovative drugs and drug candidates with global partners since 2018.